biostudies-literatureLacey CNIDCD NIH HHSU.S. Department of Veterans Affairse71566https://www.ebi.ac.uk/biostudies/studies/S-EPMC12906773biostudies-literatureUnknown15(2)<h4>Purpose</h4>Identify factors influencing audiological care for chemotherapy-induced ototoxicity from the perspectives of oncology providers in the Veterans Health Administration (VA), and quantify audiology service use among Veterans receiving ototoxic chemotherapies.<h4>Methods</h4>We surveyed VA oncology providers to identify barriers and facilitators to ototoxicity management (OtoM). We also conducted a VA-wide retrospective cohort analysis over a 5-year period to quantify audiology service use among Veterans who received cisplatin, carboplatin, or oxaliplatin chemotherapy.<h4>Results</h4>A total of 30,643 Veterans received platinum-based chemotherapy from 2014 to 2019. Few of them (< 10% on cisplatin, < 5% on carboplatin or oxaliplatin) accessed audiology services within a year of Cancer medicineIdentifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey.PMC12906773RX003127RX22019RX002361T35DC008764Milnes TGraff JNDebacker JRClark KStuehm HLacey CHungerford MJohansson KKonrad-Martin DMannino RfalseIdentifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey.<h4>Purpose</h4>Identify factors influencing audiological care for chemotherapy-induced ototoxicity from the perspectives of oncology providers in the Veterans Health Administration (VA), and quantify audiology service use among Veterans receiving ototoxic chemotherapies.<h4>Methods</h4>We surveyed VA oncology providers to identify barriers and facilitators to ototoxicity management (OtoM). We also conducted a VA-wide retrospective cohort analysis over a 5-year period to quantify audiology service use among Veterans who received cisplatin, carboplatin, or oxaliplatin chemotherapy.<h4>Results</h4>A total of 30,643 Veterans received platinum-based chemotherapy from 2014 to 2019. Few of them (< 10% on cisplatin, < 5% on carboplatin or oxaliplatin) accessed audiology services within a year of 2026-01-01T00:00:00Z2026 Feb2026-07-15T16:37:09.705Z2026-07-07T03:08:20.453ZS-EPMC129067734169161010.1002/cam4.71566